DIBH

Accuray Initiates Sales of the VitalHold™ Solution in Japan, Supporting Surface-guided Radiation Therapy on the Radixact® System

Retrieved on: 
Tuesday, December 5, 2023
Radiation, DIBH, Risk, Breast cancer, Patient, Heart, Breast, Cancer, Neoplasm, Medical imaging

MADISON, Wis., Dec. 5, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company has initiated sales of the VitalHold™* package supporting surface-guided radiation therapy (SGRT) on the Radixact® System in Japan beginning November 30, 2023.

Key Points: 
  • MADISON, Wis., Dec. 5, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company has initiated sales of the VitalHold™* package supporting surface-guided radiation therapy (SGRT) on the Radixact® System in Japan beginning November 30, 2023.
  • The addition of this new feature will enable medical teams using the Radixact System to offer a wider range of radiotherapy treatment options using one device.
  • SGRT technology, which helps confirm the patient is appropriately positioned to deliver radiation, is widely used to facilitate these treatments.
  • "We are very pleased to now offer VitalHold to our customers to support surface-guided radiotherapy using the Radixact System.

Accuray and Limbus AI Unveil Online Adaptive Therapy Solution for the Radixact® System at American Society for Radiation Oncology (ASTRO) Annual Meeting

Retrieved on: 
Monday, October 2, 2023
SBRT, Cyberknife, SRS, CE, Radiation, Partnership, DIBH, Workflow, Alliance University (New York City), Neoplasm, ASTRO, Cancer, Radiation therapy, Sale, Limbus, Patient, Risk, Annual general meeting, Physics, Society, American Society for Radiation Oncology, Software, Medical device, Medical imaging, EU, Accuray, Ceno

The solution was unveiled, in partnership with Limbus AI, at the 2023 ASTRO (American Society for Radiation Oncology) Annual Meeting in San Diego, California, October 1-4, 2023.

Key Points: 
  • The solution was unveiled, in partnership with Limbus AI, at the 2023 ASTRO (American Society for Radiation Oncology) Annual Meeting in San Diego, California, October 1-4, 2023.
  • Accuray customers are currently able to leverage real-time adaptive therapy through the company's proprietary Synchrony® technology and offline adaptive with PreciseART® radiotherapy to account for some of the anatomical changes that occur during radiation delivery.
  • "We're very happy to be partnering with Accuray," said Dr Karl Otto, CEO of Limbus AI.
  • Embedding it into the Cenos online adaptive solution will help provide for accurate and fast contouring essential to real-world clinical implementation of adaptive treatment."

Accuray Receives FDA Clearance for VitalHold™ on the Radixact® System; Breast Cancer Treatment Option Will Also Be Available in the EU Market

Retrieved on: 
Thursday, August 10, 2023
Tissue, CT, Radiation, DIBH, Life, Cancer, Woman, Breast, National Cancer Institute, Patient, Risk, Lymph, Oar, Neoplasm, System, FDA, Breast cancer, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Medical imaging, EU, Accuray

The treatment option will also be available in the EU market.

Key Points: 
  • The treatment option will also be available in the EU market.
  • With the addition of this new functionality, the Radixact System offers a comprehensive tool set for the treatment of breast cancer.
  • Now, Accuray can offer our customers the widest range of radiation treatment delivery techniques in one device, the Radixact System.
  • According to the National Cancer Institute, breast cancer is the most common cancer diagnosed in women in the U.S., other than skin cancers1.

Accuray CyberKnife® and TomoTherapy® Platforms Featured in More Than 55 Abstracts Presented at ESTRO 2023, Reinforcing Systems' Versatility, Efficiency and Effectiveness

Retrieved on: 
Wednesday, May 17, 2023
Pancreatic cancer, Cyberknife, SBRT, Abstract, CE, Deep inspiration breath-hold, SRS, Radiation, Health care, DIBH, Prostate cancer, Metastasis, Cosmesis, Cancer, Quality of life, Lung cancer, Toxicity, MBA, Brain, Prostate, Sale, Movement, Synchrony, Radiation therapy, Motion, LINAC, Patient, Tomotherapy, Breast, Ultra, Accuracy and precision, Neoplasm, European Society for Medical Oncology, Congress, Health, Recurrence, Melphalan, Safety, Pharmaceutical industry, Medical imaging, Medical device, Dairy, Accuray

SUNNYVALE, Calif., May 17, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that new data presented at the European Society for Radiotherapy and Oncology (ESTRO) meeting reinforces the benefits of the company's CyberKnife® and TomoTherapy® platforms, including the latest generation Radixact® System. More than 55 abstracts highlighting Accuray technologies were presented at the 2023 ESTRO annual congress held in Vienna, Austria, from May 12 to May 16, 2023, building on existing clinical evidence and supporting the systems' use to deliver (ultra) hypofractionated radiation treatments for the precise and personalized treatment of a wide range of cancers.

Key Points: 
  • During the meeting, Accuray hosted a symposium titled " Advances in Hypofractionation for Breast and Prostate Cancer " featuring clinical experts who discussed the most recent – and promising – clinical studies.
  • "The information sharing that takes place at meetings such as ESTRO is focused on the same critical goal – improving patient care.
  • Delivering ablative doses to target spinal metastases, ensuring good local control and low rates of toxicity while protecting critical organs5.
  • It is not CE marked and availability is subject to regulatory clearance or approval in some markets.

Accuray and C-RAD Unveil Automated Breast Cancer Treatment Package for the Radixact® System at American Society for Radiation Oncology (ASTRO) Annual Meeting

Retrieved on: 
Thursday, October 13, 2022
LinkedIn, NASDAQ, Standard of care, Awareness, Data, AI, Deep inspiration breath-hold, CEO, Calibration, YouTube, Twitter, Symposium, Annual general meeting, Cancer, Private Securities Litigation Reform Act, National Cancer Institute, Industry, ASTRO, Breast cancer, TPS, CE, Breast Cancer Awareness Month, Time, Woman, Diagnosis, Solution, Annual report, Society, Security (finance), Radiation therapy, Artemis, U.S. Securities and Exchange Commission, National, Radiation, DIBH, Risk, Disease, Sale, SEC, Workflow, Neoplasm, Patient, Hospital, Partnership, American Society for Radiation Oncology, RaySearch Laboratories, Safety, Forward-looking statement, Heart, COVID-19, 2022 Formula One World Championship, Medical imaging, Medical device, Facebook, Software

Meeting attendees are invited to attend the U.S. unveiling of a new breast cancer treatment package* for the Radixact System at the Accuray booth, #2586, on Sunday, October 23, 2022 at 10:30 am CT.

Key Points: 
  • Meeting attendees are invited to attend the U.S. unveiling of a new breast cancer treatment package* for the Radixact System at the Accuray booth, #2586, on Sunday, October 23, 2022 at 10:30 am CT.
  • According to the National Cancer Institute, breast cancer is the most common cancer diagnosed in women in the U.S., other than skin cancers1.
  • Treatment for breast cancer represents more than 20 percent of cases seen by radiation oncology departments3,4.
  • The breast cancer treatment package [name to be revealed during the unveiling at ASTRO] is not available for sale in the USA.

Breast Cancer Patients Now Have New Radiation Treatment Option that Visualizes the Heart and Addresses Co-Morbidities

Retrieved on: 
Thursday, August 11, 2022
Software, Radiology, Pharmaceutical, Oncology, Consumer, Medical Devices, Technology, Clinical Trials, Women, Biotechnology, FDA, Health, Woman, JD, Multimedia, Survival, CMF, Deep inspiration breath-hold, Risk, Radiation, Lung cancer, DIBH, Obesity, Radiosurgery, Technology, Cancer, Spine, Facebook, Radiation therapy, Hospital, Trauma, Government, Patient, Instagram, Twitter, Breast cancer, Cardiotoxicity, Brainlab, Physician, Heart, MD, LinkedIn, Neurosurgery, Medical imaging

(Source: Brainlab)

Key Points: 
  • (Source: Brainlab)
    Breast cancer is the most prevalent cancer for women in the United States and second most deadly cancer for females according to the US government and breast cancer advocacy groups.
  • In the ongoing pursuit of curative radiation treatment, clinicians find that they may undesirably irradiate the heart while attempting to eradicate breast cancer for left-sided cancer patients, as unmanaged breathing may bring the vital organ into the radiation targeting field.
  • Until now, patients receiving breast cancer radiation treatments have been typically treated using large treatment margins and without the benefit of internal anatomical verification during treatment.
  • By incorporating on-the-fly X-Ray confirmation, Brainlab technology streamlines the process and delivers confidence that the heart is outside of the treatment beam.

UZ Brussel First to Treat Breast Cancer Patients with New Brainlab Deep Inspiration Breath Hold with Instant X-Ray Confirmation

Retrieved on: 
Thursday, May 19, 2022
Software, Radiology, Biotechnology, Hardware, Oncology, Health, Medical Devices, Technology, Brainlab, Physician, Risk, Population, Breast cancer, Radiosurgery, DIBH, Multimedia, Patient, Trauma, Workflow, Vrije Universiteit Brussel, Radiation, CE, Research, FDA, Facebook, CMF, Neurosurgery, Instagram, Hospital, Technology, Heart, Cardiotoxicity, LinkedIn, IGRT, Twitter, Spine, Deep inspiration breath-hold, Internal, CEO, Medical imaging

UZ Brussel is a university hospital at the Vrije Universiteit Brussel with 721 hospital beds and almost 4,000 employees.

Key Points: 
  • UZ Brussel is a university hospital at the Vrije Universiteit Brussel with 721 hospital beds and almost 4,000 employees.
  • (Source: Brainlab)
    Deep Inspiration Breath Hold is a well-established technique and standard of care in treating breast cancer with radiation therapy.
  • When a patient takes a deep breath, the distance between the heart and the chest cavity is increased, reducing the risk of cardiac toxicity during breast cancer treatment.
  • Were excited to be the first to use this game changing positioning and breath hold control in breast cancer patients without skin marks.

DYN’R Medical Systems and Mevion announce the launch of the SDX® Respiratory Gating System synchronized interface with MEVION S250i and the completion of the installation at OU Health.

Retrieved on: 
Thursday, October 21, 2021
Research, Medical Devices, Hospitals, Radiology, Health, General Health, Other Science, Science, Oncology, Proton, Science, Lung, Solution, American Society for Radiation Oncology, Breast cancer, Verification, Efficiency, Patient safety, V&V, Norris Production Solutions, Cancer, Industry, OU Health, Radiation therapy, Neoplasm, Partnership, Patient, SDX, Breast, Proton therapy, Spirometry, CEO, NCI, Multimedia, DIBH, ASTRO, Varian Medical Systems, Society, Medical imaging, Risk management

DYNR Medical Systems and Mevion Medical Systems, the leader in compact proton therapy, are delighted to announce the launch of a new gating option for their joint customers.

Key Points: 
  • DYNR Medical Systems and Mevion Medical Systems, the leader in compact proton therapy, are delighted to announce the launch of a new gating option for their joint customers.
  • The SDX System is the most effective proton therapy respiratory monitoring solution, especially during the lung, breast and liver treatments.
  • The development of the synchronized interface with MEVION S250i was an important target of our business development plan said Francois Galzin, President & CEO of DYNR Medical Systems.
  • Since 2004, Mevion Medical Systems has been the leading provider of compact proton therapy systems for cancer care.